Profile cover photo
Profile photo
Pharma 14
2 followers -
https://www.pharma14.com/ - Global Medicine Database, Medicine Price, Drug Prices and Drug Database
https://www.pharma14.com/ - Global Medicine Database, Medicine Price, Drug Prices and Drug Database

2 followers
About
Posts

Post has attachment
Add a comment...

Post has attachment
“Opportunity is where you find it” - TRAZODONE - Pharma14
Trazodone - Older generic products becoming niche products.
For many generic pharmaceutical companies being able to locate a niche market that offers a unique opportunity with a sizeable market potential and few competitors is a very good starting point.

We at Pharma14 recognize this need and our monthly updated database of 39 countries with over 1 million market authorizations gives our customers a unique insight into the medicine market on a live macro level.

For example, let’s have a look at the antidepressant drug Trazodone.


Table 1: Market size for Trazodone (@pharma14)

Our database teaches us that although Trazodone has a sizeable market (see table 1) there are only a few MA holders competing for these markets (see table 2). Furthermore the market for Trazodone has been growing at double digit rates the last few years. A notable country is Italy. Italy’s $17M/year market is dominated by a single provider!


Table 2: MA holders for Trazodone in various European markets (@pharma14)

Bottom line: Opportunity is where you find it! And with Pharma14's global medicine database it just got a lot easier.

PHARMA14 HIGHLIGHTS:

• 39 full country medicine database. The countries we cover - https://www.pharma14.com/StaticPages/Features

• 1,000,000 medicines - full information about each drug including - Ex-factory, Wholesale and retail prices + reimbursed information.

• We have recently added Brazil and Russia to our platform.

• First approval date and marketing authorizations for all molecules from USA, Europe and EU15
Add a comment...

Post has shared content
Upgrading Drug Database
Russia added to Pharma14 global medicine database
The Russian Pharmaceutical market is currently valued at $21 billion and is set to rise to close to $40 billion by 2022. This steep growth curve serves as a reminder to the potential of this market who has a population of 144 million people.

One of the great drivers of this growth is the federal drug reimbursement program. The VED - Vital and Essential Drugs list is comprised of hundreds of drugs that are fully covered by the Russian state.

Keeping informed about this important market is key in order to participate in it. Pharma14 has currently added the Russian pharmaceutical market to its database with over 20,000 medicines including all pricing.

Post has attachment
Russia added to Pharma14 global medicine database.
The Russian Pharmaceutical market is currently valued at $21 billion and is set to rise to close to $40 billion by 2022. This steep growth curve serves as a reminder to the potential of this market who has a population of 144 million people.

One of the great drivers of this growth is the federal drug reimbursement program. The VED - Vital and Essential Drugs list is comprised of hundreds of drugs that are fully covered by the Russian state.

Keeping informed about this important market is key in order to participate in it. Pharma14 has currently added the Russian pharmaceutical market to its database with over 20,000 medicines including all pricing.

Our pricing data includes ex-factory, wholesale and retail pricing as well as all reimbursed data. All our data is updated monthly including the changes in the VED and the much larger Essential Drug list. The data in Pharma14 has all been translated to English including molecule information, MA holder data and more.


All prices are in local RUB but can be easily converted into over 150 different currencies of your choice using our live conversion application.

Combined with your own knowledge it provides a powerful market intelligence tool as well as a means of assisting in managing your portfolio of products.

The information available assists those working in regulatory affairs, marketing, product acquisitions, business intelligence and others.

About Pharma14.

Pharma14 is a global medicine database and price knowledge platform.

An excellent tool for in-license, out-license, business development and many other pharmaceutical industry decision makers.

Our medicine database covers all Marketing Authorizations across 38 markets - Europe, North America and more.

Our price index covers all of the above + has all official prices - ex-factory, wholesale and retail.

Pharma14 - HIGHLIGHTS:

• 39 full country medicine database.

• 1,000,000 medicines - full information about each drug.

• Medicine prices include Ex-factory, Wholesale and retail + reimbursed information.

• Monthly updates on all data.

• Active ingredients, ATC levels, administration routes, strength, trade names, MA holder information, real manufacturer information, leaflets in PDF format and much more.

• MOST AFFORDABLE YEARLY MEMBERSHIPS IN THE INDUSTRY
Add a comment...

Russia added to Pharma14 global medicine database
The Russian Pharmaceutical market is currently valued at $21 billion and is set to rise to close to $40 billion by 2022. This steep growth curve serves as a reminder to the potential of this market who has a population of 144 million people.

One of the great drivers of this growth is the federal drug reimbursement program. The VED - Vital and Essential Drugs list is comprised of hundreds of drugs that are fully covered by the Russian state.

Keeping informed about this important market is key in order to participate in it. Pharma14 has currently added the Russian pharmaceutical market to its database with over 20,000 medicines including all pricing.

Post has attachment
Add a comment...

Post has attachment

Post has attachment

Post has attachment

Post has attachment
Pharma14 is happy to announce a new addition to our global medicine database platform. Beginning this week all medicine information data will be enhanced with the earliest registration dates in the USA and European markets.
This information will greatly benefit our members interested in timing and planning their R&D projects and marketing applications as well as searching for new business development opportunities.
Sample earliest registration date for Humira - Adalimumab.
Photo
Add a comment...
Wait while more posts are being loaded